27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Scale of benefit is comparable with in-person training, indicating its potential as a public health intervention. 3 key findings →
Design: randomized controlled trial Participants: 2,912 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The pathophysiological process of Alzheimer's disease (AD) is thought to begin many years before the diagnosis of AD dementia. 5 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
These results suggest that frequent participation in cognitively stimulating activities is associated with reduced risk of AD. 5 key findings →
Design: cohort study Participants: 111 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
We have demonstrated that three baseline measures, namely, age >or=72 years, semantic fluency less than 20 words in 90 s and inability to copy an intersecting pentagons figure, are significant predictors of dementia risk, thus validating our previous findings. 5 key findings →
Design: cross-sectional Participants: 126 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Besides the MMSE, there are many other tests with comparable diagnostic performance for detecting dementia. 4 key findings →
Participants: 102 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
This analysis of 2-year retrospective cohort studies of individuals diagnosed with COVID-19 showed that the increased incidence of mood and anxiety disorders was transient, with no overall excess of these diagnoses compared with other respiratory infections. 5 key findings →
Design: cohort study Participants: 47 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
81 participants with probable Alzheimer's disease and 69 healthy controls were assessed. 1 key finding →
Design: clinical trial Participants: 81 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Those reporting depressive symptoms in 1985 (mean follow-up, 27 years) did not have significantly increased risk for dementia (hazard ratio [HR], 1.21; 95% CI, 0.95-1.54) in Cox regression adjusted for sociodemographic covariates, health behaviors, and chronic conditions. 5 key findings →
Design: cohort study Participants: 322 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Elderly people taking anticholinergic drugs had significant deficits in cognitive functioning and were highly likely to be classified as mildly cognitively impaired, although not at increased risk for dementia. 4 key findings →
Design: cohort study Participants: 372 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Abnormal aggregates of the synaptic protein, α-synuclein, are the dominant pathology in syndromes known as the synucleinopathies. 1 key finding →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Of more than 50 articles identified, the overwhelming majority did not meet inclusion criteria, primarily because of lack of clear diagnoses of dementia and AD. 3 key findings →
Design: meta-analysis Participants: 212 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Parietal cortex RNA-sequencing (RNA-seq) data were generated from individuals with and without Alzheimer disease (AD; n control = 13; n AD = 83) from the Knight Alzheimer Disease Research Center (Knight ADRC). 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
In older cognitively unimpaired individuals (≥50 years), widespread, age-related elevated tau signal was seen among those with normal or abnormal amyloid status as compared to younger cognitively unimpaired individuals (30-49 years). 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
In the discovery cohort, the mean (SD) age was 70.9 (8.5) years, 191 (58%) were male, the mean (SD) MMSE score was 27.1 (1.9), and 110 individuals with MCI (33%) converted to dementia (71 to AD dementia). 4 key findings →
Design: cohort study Participants: 110 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
APOE ε4 may influence the association between WMH and cognitive performance in AD and DLB. 5 key findings →
Design: meta-analysis Participants: 167 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The findings of this review provide insight into catalysing the paradigm shift from 'reducing stress' to 'optimising positive experience' in developing caregiving support services for dementia, and may guide future empirical study to explain this unique dimension of caregiving experience. 2 key findings →
Design: cohort study Participants: 3,862 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
There were 987 participants (290 from Vantaa 85+, 241 from the Cambridge City Over-75s Cohort, and 456 from the Cognitive Function and Ageing Study) with neuropathologic data; mean (SD) age at death was 90 (6.4) years, including 682 women (69%). 5 key findings →
Design: cohort study Participants: 987 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Use of donepezil by AD patients resulted in significant delays in NHP. 2 key findings →
Design: open-label trial Participants: 1,115 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Although mixed, the results indicate a positive response for the use of internet-based interventions by caregivers. 4 key findings →
Participants: 40 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Depression, anxiety, and apathy symptoms are highly prevalent across dementia stages. 2 key findings →
Design: meta-analysis Participants: 5,897 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Existing studies have included a narrow range of infectious diseases, relied on short follow-up periods, and provided little evidence for whether the increased risk is limited to specific dementia subtypes or attributable to specific microbes rather than infection burden. 5 key findings →
Design: cohort study Participants: 490 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Brain clocks, which quantify discrepancies between brain age and chronological age, hold promise for understanding brain health and disease. 4 key findings →
Participants: 5,306 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Dementia diagnosis recording in general hospitals is increasing but remains less likely in some groups. 1 key finding →
Design: cohort study Participants: 21,387 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
This study provides a quantitative synthesis of the prospective associations between personality traits (neuroticism, extraversion, openness, agreeableness, conscientiousness) and the risk of incident Alzheimer's disease and related dementias. 3 key findings →
Design: meta-analysis Participants: 30,036 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Low-dose aspirin did not prevent depression in this large-scale study of otherwise healthy older adults. 3 key findings →
Participants: 114 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →